Bill Ackman’s hedge fund, Pershing Square Capital Management may be the second biggest owner of Valeant Pharmaceuticals International Inc., but the fund’s diversification has helped insulate it (somewhat) from the brunt of the stocks decline. Other hedge funds haven’t been so lucky. According to Reuters, Ackman’s Pershing Square reported a decline of 6% to 7% for the month of October. Meanwhile, Jonathan Auerbach and Scott McLellan’s Hound Partners, which had a 15% position in Valeant at the end of the second quarter, dropped 7.1% in October. However, Nehal Chopra’s Tiger Ratan has recently emerged as the biggest loser of the Valeant scandal. According…
Nehal Chopra’s Tiger Ratan Takes $300 Million Hit On Valeant Pharmaceuticals International Inc.
Sign up now and get our in-depth FREE e-books on famous investors like Klarman, Dalio, Schloss, Munger Rupert is a committed value investor and regularly writes and invests following the principles set out by Benjamin Graham. He is the editor and co-owner of Hidden Value Stocks, a quarterly investment newsletter aimed at institutional investors. Rupert owns shares in Berkshire Hathaway. Rupert holds qualifications from the Chartered Institute For Securities & Investment and the CFA Society of the UK. Rupert covers everything value investing for ValueWalk
Comments are closed.